Johnson & Johnson reported Phase 3 results showing Tecvayli reduced risk of disease progression or death versus standard regimens in patients who relapsed after frontline therapy, with the company saying the drug cut the combined risk of progression or death by 71% in the MajesTEC‑9 context and reported a 40% reduction in risk of death in a related trial readout. The data come from randomized trials enrolling previously treated multiple myeloma patients. Tecvayli, a dual‑targeting bispecific antibody launched under accelerated approval for later lines, is being positioned by J&J for earlier use; the company said it will discuss results with regulators and present them at a medical meeting. FDA engagement—already highlighted by a recent “national priority” fast pass for related filings—could accelerate label expansion and market access.